ArticleClinical and experimental medicine2025
Integrated bioinformatics analysis reveals novel PANoptosis biomarkers and therapeutic response in clear cell renal cell carcinoma.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent advances in PANoptosis research in kidney disease: mechanistic networks, pathological roles, and potential intervention strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma (ccRCC) is the most common type of RCC. Apoptosis, pyroptosis, and necroptosis are key regulatory processes in carcinogenesis. Accumulating evidence indicated significant crosstalk among three forms of cell death, which is termed as the PANoptosis. However, the connection between PANoptosis and ccRCC remains uncertain. Here, we utilized the TCGA and GEO database to explore distinct PANoptosis patterns based on 62 PANoptosis genes and investigated the clinical, biological, and immune cell infiltration characteristics of PANoptosis patterns. Then, we identified prognosis-related genes from PANoptosis patterns and developed a scoring system that effectively predicts clinical outcomes of ccRCC patients. We also explored the expression of key regulators to confirm these identifications. Immunological analyses revealed a positive correlation between risk score and M0 type macrophages, activated mast cells, follicular helper T cells, and regulatory T cells. Finally, the risk model demonstrated the ability to predict drug sensitivity for ccRCC, such as sorafenib, rapamycin and pazopanib. In conclusion, our findings offer novel insights into the role of PANoptosis in ccRCC and identify potential targets for controlling ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.